Physician profile
Christopher Boyce
NPI 1326537077
$742.73
in general payments reported to CMS, 2019-2025
15 companies · $743 in 2025
The $743 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $146.82 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $89.47 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $77.91 | 2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $67.94 | 2025 | Jardiance |
| Medtronic, INC. | $51.00 | 2025 | Minimed 780g |
| Radius Health, INC. | $50.79 | 2025 | Tymlos |
| Tandem Diabetes Care, INC. | $49.33 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $38.11 | 2025 | Omnipod |
| Beta Bionics, INC. | $36.85 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $29.74 | 2025 | Rezdiffra |
| Cequr Corporation | $29.54 | 2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $22.36 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $20.13 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.77 | 2025 | Jardiance |
| Novo Nordisk INC | $14.97 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Boyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.